Search Within

Min Yuen Teo

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (19)
  3. Editorial (1)
Groups
  1. Department of Medicine (41)
  2. Epidemiology and Biostatistics (41)
  3. Genitourinary Oncology Service (41)
  4. Solid Tumor Oncology Division (41)
  5. Biostatistics Service (37)
  6. Weinberg Fellows (31)

More Groups

People
  1. Gopakumar Iyer (37)
  2. Jonathan Rosenberg (35)
  3. Dean Bajorin (31)
  4. Irina Ostrovnaya (30)
  5. Hikmat Al-Ahmadie (27)
  6. Samuel Funt (27)

More People

Years
  1. 2024 (7)
  2. 2023 (2)
  3. 2022 (11)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (5)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Cancer Research (2)
  3. Clinical Cancer Research (2)
  4. Clinical Genitourinary Cancer (2)
  5. European Urology (2)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (23)
  2. American Association for Cancer Research (4)
  3. Cell Press (2)
  4. Elsevier Inc. (2)
  5. Elsevier Science, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (41)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Differential NEUROD1, ASCL1, and POU2F3 expression defines molecular subsets of bladder small cell/neuroendocrine carcinoma with prognostic implications
    Journal Article

    Akbulut, D.; Whiting, K.; Teo, M. Y.; Tallman, J. E.; Ozcan, G. G.; Basar, M.; Jia, L.; Rammal, R.; Chen, J. F.; Sarungbam, J.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer
    Journal Article

    Lenis, A. T.; Whiting, K.; Ravichandran, V.; Tallman, J. E.; Alam, S. M.; Chu, C. E.; De Jesus Escano, M.; Bochner, E.; Katims, A.; Reisz, P. A.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Hypofractionated radiation therapy (Hypo-RT) for the treatment of localized bladder cancer
    Journal Article

    Moore, A.; Lobaugh, S. M.; Zhang, Z.; Rosenberg, J. E.; Iyer, G.; Teo, M. Y.; Bochner, B.; Donahue, T.; Nunez, D. A.; Dreyfuss, A.; more...
    Bladder Cancer (2023)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)
    Meeting Abstract

    Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of bladder carcinomas with glandular phenotype
    Journal Article

    Almassi, N.; Whiting, K.; Toubaji, A.; Lenis, A. T.; Jordan, E. J.; Won, H.; Regazzi, A. M.; Chen, Y. B.; Gopalan, A.; Sirintrapun, S. J.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save